Related references
Note: Only part of the references are listed.Fibroblast Growth Factor Receptors-1 and-3 Play Distinct Roles in the Regulation of Bladder Cancer Growth and Metastasis: Implications for Therapeutic Targeting
Tiewei Cheng et al.
PLOS ONE (2013)
The anticancer multi-kinase inhibitor dovitinib also targets topoisomerase I and topoisomerase II
Brian B. Hasinoff et al.
BIOCHEMICAL PHARMACOLOGY (2012)
Small molecule FGF receptor inhibitors block FGFR-dependent urothelial carcinoma growth in vitro and in vivo
F. R. Lamont et al.
BRITISH JOURNAL OF CANCER (2011)
Mechanism of the Mesenchymal-Epithelial Transition and Its Relationship with Metastatic Tumor Formation
Dianbo Yao et al.
MOLECULAR CANCER RESEARCH (2011)
Transcriptional crosstalk between TGFβ and stem cell pathways in tumor cell invasion Role of EMT promoting Smad complexes
Jonas Fuxe et al.
CELL CYCLE (2010)
Cadherin Switching and Bladder Cancer
Richard T. Bryan et al.
JOURNAL OF UROLOGY (2010)
Roles for Growth Factors in Cancer Progression
Esther Witsch et al.
PHYSIOLOGY (2010)
Fibroblast growth factor signalling: from development to cancer
Nicholas Turner et al.
NATURE REVIEWS CANCER (2010)
Molecular Pathogenesis and Diagnostics of Bladder Cancer
Anirban P. Mitra et al.
ANNUAL REVIEW OF PATHOLOGY-MECHANISMS OF DISEASE (2009)
Role of epithelial-to-mesenchymal transition (EMT) in drug sensitivity and metastasis in bladder cancer
David J. McConkey et al.
CANCER AND METASTASIS REVIEWS (2009)
Fibroblast Growth Factor Receptor 1 Promotes Proliferation and Survival via Activation of the Mitogen-Activated Protein Kinase Pathway in Bladder Cancer
Darren C. Tomlinson et al.
CANCER RESEARCH (2009)
P-cadherin as a prognostic indicator and a modulator of migratory behaviour in bladder carcinoma cells
Jessica A. Mandeville et al.
BJU INTERNATIONAL (2008)
Sensitivity to epidermal growth factor receptor inhibitor requires E-cedherin expression in urothelial carcinoma cells
Peter C. Black et al.
CLINICAL CANCER RESEARCH (2008)
Cadherin switching dictates the biology of transitional cell carcinoma of the bladder:: ex vivo and in vitro studies
R. T. Bryan et al.
JOURNAL OF PATHOLOGY (2008)
Cadherins and cancer: how does cadherin dysfunction promote tumor progression?
A. Jeanes et al.
ONCOGENE (2008)
FGFR3 protein expression and its relationship to mutation status and prognostic variables in bladder cancer
D. C. Tomlinson et al.
JOURNAL OF PATHOLOGY (2007)
Knockdown by shRNA identifes S249C mutant FGFR3 as a potential therapeutic target in bladder cancer
D. C. Tomlinson et al.
ONCOGENE (2007)
Molecular correlates of gefitinib responsiveness in human bladder cancer cells
Marissa Shrader et al.
MOLECULAR CANCER THERAPEUTICS (2007)
Opinion - Angiogenesis: an organizing principle for drug discovery?
Judah Folkman
NATURE REVIEWS DRUG DISCOVERY (2007)
Defining molecular profiles of poor outcome in patients with invasive bladder cancer using oligonucleotide microarrays
M Sanchez-Carbayo et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Complex networks orchestrate epithelial-mesenchymal transitions
JP Thiery et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2006)
Bladder cancer outcome and subtype classification by gene expression
E Blaveri et al.
CLINICAL CANCER RESEARCH (2005)
In vivo target modulation and biological activity of CHIR-258, a multitargeted growth factor receptor kinase inhibitor, in colon cancer models
SH Lee et al.
CLINICAL CANCER RESEARCH (2005)
Diverse cellular and molecular mechanisms contribute to epithelial plasticity and metastasis
S Grünert et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2003)
Frequency of fibroblast growth factor receptor 3 mutations in sporadic tumours
K Sibley et al.
ONCOGENE (2001)
Expression of classic cadherins type I in urothelial neoplastic progression
KM Rieger-Christ et al.
HUMAN PATHOLOGY (2001)
Share Paper
